Combination therapy of pegylated interferon and lamivudine and optimal controls for chronic hepatitis B infection

Ciupe SM, Ribeiro RM, Nelson PW, Perelson AS (2007) Modeling the mechanisms of acute hepatitis B virus infection. J Theor Biol 247(1):23–35 Lewin S, Walters T, Locarnini S (2002) Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies. Antivir Res 55(3):381–396 Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, Chisari FV (2003) CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 77(1):68–76 Ribeiro RM, Lo A, Perelson AS (2002) Dynamics of hepatitis B virus infection. Microbes Infect 4(8):829–835 Dahari H, Shudo E, Ribeiro RM, Perelson AS (2009) Modeling complex decay profiles of hepatitis B virus during antiviral therapy. Hepatology 49(1):32–38 Murray JM, Purcell RH, Wieland SF (2006) The half-life of hepatitis B virions. Hepatology 44(5):1117–1121 Asselah T, Lada O, Moucari R, Martinot M, Boyer N, Marcellin P (2007) Interferon therapy for chronic hepatitis B. Clin Liver Dis 11(4):839–849 Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, Moorat A, Barber J, Gray DF (2000) Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 46(4):562–568 Severini A, Liu XY, Wilson JS, Tyrrell DL (1995) Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-\(2^{\prime },3^{\prime }\)-dideoxy-\(3^{\prime }\)-thiacytidine. Antimicrob Agents Chemother 39(7):1430–1435 Zoulim F (2004) Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antivir Res 64(1):1–15 Lewin SR, Ribeiro RM, Walters T, Lau GK, Bowden S, Locarnini S, Perelson AS (2001) Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 34(5):1012–1020 Dahari H, Lo A, Ribeiro RM, Perelson AS (2007) Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. J Theor Biol 247(2):371–381 Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103–107 Lenhart S, Workman JT (2007) Optimal control applied to biological models. Chapman and Hall/CRC, London Swan GW (1990) Role of optimal control theory in cancer chemotherapy. Math Biosci 101(2):237–284 Murray JM (1990) Some optimal control problems in cancer chemotherapy with a toxicity limit. Math Biosci 100(1):49–67 Murray JM (1990) Optimal control for a cancer chemotherapy problem with general growth and loss functions. Math Biosci 98(2):273–287 de Pillis LG, Gu W, Fister KR, Head T, Maples K, Murugan A, Neal T, Yoshida K (2007) Chemotherapy for tumors: an analysis of the dynamics and a study of quadratic and linear optimal controls. Math Biosci 209(1):292–315 Fister KR, Panetta JC (2003) Optimal control applied to competing chemotherapeutic cell-kill strategies. SIAM J Appl Math 63(6):1954–1971 Chavez IYS, Morales-Menendez R, Chapa SOM (2009) Glucose optimal control system in diabetes treatment. Appl Math Comput 209(1):19–30 Nanda S, Moore H, Lenhart S (2007) Optimal control of treatment in a mathematical model of chronic myelogenous leukemia. Math Biosci 210(1):143–156 Kirschner D, Lenhart S, Serbin S (1997) Optimal control of the chemotherapy of HIV. J Math Biol 35(7):775–792 Joshi HR (2002) Optimal control of an HIV immunology model. Optim Control Appl Methods 23(4):199–213 Adams BM, Banks HT, Davidian M, Kwon H-D, Tran HT, Wynne SN, Rosenberg ES (2005) HIV dynamics: modeling, data analysis, and optimal treatment protocols. J Comput Appl Math 184(1):10–49 Stengel RF (2008) Mutation and control of the human immunodeficiency virus. Math Biosci 213(2):93–102 Chakrabarty SP, Joshi HR (2009) Optimally controlled treatment strategy using interferon and ribavirin for hepatitis C. J Biol Syst 17(1):97–110 Chakrabarty SP (2009) Optimal efficacy of ribavirin in the treatment of hepatitis C. Optim Control Appl Methods 30(6):594–600 Pachpute G, Chakrabarty SP (2013) Dynamics of hepatitis C under optimal therapy and sampling based analysis. Commun Nonlinear Sci Numer Simul 18(8):2202–2212 Martin NK, Pitcher AB, Vickerman P, Vassall A, Hickman M (2011) Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users. PLoS ONE 6(8):e22309 Manna K, Chakrabarty SP (2015) Chronic hepatitis B infection and HBV DNA-containing capsids: modeling and analysis. Commun Nonlinear Sci Numer Simul 22(1–3):383–395 Srivastava PK, Chandra P (2010) Modeling the dynamics of HIV and CD4+ T cells during primary infection. Nonlinear Anal Real World Appl 11(2):612–618 van den Driessche P, Watmough J (2002) Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. Math Biosci 180(1–2):29–48 Heffernan JM, Smith RJ, Wahl LM (2005) Perspectives on the basic reproductive ratio. J R Soc Interface 2(4):281–293 Adams BM, Banks HT, Kwon H-D, Tran HT (2004) Dynamic multidrug therapies for HIV: optimal and STI control approaches. Math Biosci Eng 1(2):223–241 Fister KR, Lenhart S, McNally JS (1998) Optimizing chemotherapy in an HIV model. Electron J Differ Equ 32:1–12 Fleming WH, Rishel RW (1975) Deterministic and stochastic optimal control. Springer, Berlin Garira W, Musekwa SD, Shiri T (2005) Optimal control of combined therapy in a single strain HIV-1 model. Electron J Differ Equ 52:1–22 Chakrabarty SP, Banerjee S (2010) A control theory approach to cancer remission aided by an optimal therapy. J Biol Syst 18(1):75–91 Burden T, Ernstberger J, Fister KR (2004) Optimal control applied to immunotherapy. Discrete Cont Dyn Syst Ser B 4(1):135–146 Kirk DE (2004) Optimal control theory: an introduction. Dover Publications, Mineola